Abstract
Purpose
Advanced ovarian clear cell carcinoma (OCCC) is a recalcitrant disease, often resistant to the first-line platinum-based therapy. Using a novel patient-derived orthotopic xenograft (PDOX) nude-mouse model of OCCC, we tested whether oral-recombinant methioninase (o-rMETase) could enhance the efficacy of paclitaxel (PTX).
Methods
The OCCC PDOX model was established and passaged in nude mice. The OCCC PDOX models were randomized into 5 groups. G1: untreated control; G2: paclitaxel (PTX) (20 mg/kg, intraperitoneal (i.p.) injection, weekly); G3: o-rMETase (100 units, oral, daily); G4: PTX (20 mg/kg, i.p. injection, weekly) + carboplatinum (CBDCA) (40 mg/kg, i.p. injection weekly); G5: PTX (20 mg/kg, i.p. injection, weekly) + o-rMETase (100 units, oral, daily). The treatment period was 2 weeks.
Results
The combination of PTX and o-rMETase arrested OCCC tumor growth (relative tumor volume: 1.09 ± 0.63 (mean ± SD)) compared with the untreated control (relative tumor volume: 3.92 ± 1.04 (mean ± SD)) (p < 0.0001). There was no significant difference in relative tumor volume between PTX plus o-rMETase and PTX plus CBDCA (relative tumor volume: 1.39 ± 0.37 (mean ± SD)) (p = 0.93).
Conclusion
PTX plus o-rMETase arrested the OCCC tumor growth. o-rMETase is readily administered and can greatly enhance first-line therapy of a recalcitrant cancer. The novel and effective treatment strategy in the present report has future clinical potential for patients with OCCC, especially for patients who cannot well tolerate platinum-based therapy.
Similar content being viewed by others
Data availability
All data and materials are available.
Code availability
Data of the present manuscript are stored on Microsoft office and GraphPad Prism.
References
Anglesio MS, Carey MS, Kobel M, Mackay H, Huntsman DG, Vancouver Ovarian Clear Cell Symposium S (2010) Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th 2011. Gynecol Oncol 121(2):407–415. https://doi.org/10.1016/j.ygyno.2011.01.005
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68(4):284–296. https://doi.org/10.3322/caac.21456
Nagase S, Ohta T, Takahashi F, Enomoto T, Committee on Gynecologic Oncology of the Japan Society of O, Gynecology (2019) Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: annual patients report for 2015 and annual treatment report for 2010. J Obstet Gynaecol Res 45(2):289–298. https://doi.org/10.1111/jog.13863
Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88(11):2584–2589
Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP, Gynecologic Oncology Group S (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25(24):3621–3627. https://doi.org/10.1200/JCO.2006.10.2517
Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM Jr, Konner JA, Aghajanian CA (2015) Ovarian clear cell carcinoma, outcomes by stage: the MSK experience. Gynecol Oncol 139(2):236–241. https://doi.org/10.1016/j.ygyno.2015.09.016
du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320–1329. https://doi.org/10.1093/jnci/djg036
Hoffman RM, Erbe RW (1976) High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine. Proc Natl Acad Sci U S A 73(5):1523–1527. https://doi.org/10.1073/pnas.73.5.1523
Hoffman RM (2015) Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey. Expert Opin Biol Ther 15(1):21–31. https://doi.org/10.1517/14712598.2015.963050
Han Q, Tan Y, Hoffman RM (2020) Oral dosing of recombinant methioninase is associated with a 70% drop in PSA in a patient with bone-metastatic prostate cancer and 50% reduction in circulating methionine in a high-stage ovarian cancer patient. Anticancer Res 40(5):2813–2819
Coalson DW, Mecham JO, Stern PH, Hoffman RM (1982) Reduced availability of endogenously synthesized methionine for S-adenosylmethionine formation in methionine-dependent cancer cells. Proc Natl Acad Sci U S A 79(14):4248–4251. https://doi.org/10.1073/pnas.79.14.4248
Stern PH, Hoffman RM (1984) Elevated overall rates of transmethylation in cell lines from diverse human tumors. In Vitro 20(8):663–670. https://doi.org/10.1007/BF02619617
Hoffman RM, Jacobsen SJ (1980) Reversible growth arrest in simian virus 40-transformed human fibroblasts. Proc Natl Acad Sci U S A 77(12):7306–7310. https://doi.org/10.1073/pnas.77.12.7306
Yano S, Li S, Han Q, Tan Y, Bouvet M, Fujiwara T, Hoffman RM (2014) Selective methioninase-induced trap of cancer cells in S/G2 phase visualized by FUCCI imaging confers chemosensitivity. Oncotarget 5(18):8729–8736
Kawaguchi K, Han Q, Li S, Tan Y, Igarashi K, Kiyuna T, Miyake K, Miyake M, Chmielowski B, Nelson SD, Russell TA, Dry SM, Li Y, Singh AS, Eckardt MA, Unno M, Eilber FC, Hoffman RM (2018) Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention. Cell Cycle 17(3):356–361. https://doi.org/10.1080/15384101.2017.1405195
Miyake K, Kiyuna T, Kawaguchi K, Higuchi T, Oshiro H, Zhang Z, Wangsiricharoen S, Razmjooei S, Li Y, Nelson SD, Murakami T, Hiroshima Y, Matsuyama R, Bouvet M, Chawla SP, Singh SR, Endo I, Hoffman RM (2019) Regorafenib regressed a doxorubicin-resistant Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model. Cancer Chemother Pharmacol 83(5):809–815. https://doi.org/10.1007/s00280-019-03782-w
Higuchi T, Miyake K, Sugisawa N, Oshiro H, Zhang Z, Razmjooei S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM (2019) The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model. Cancer Chemother Pharmacol 83(6):1075–1082. https://doi.org/10.1007/s00280-019-03824-3
Higuchi T, Sugisawa N, Yamamoto J, Oshiro H, Han Q, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Tan Y, Kuchipudi S, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM (2020) The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model. Cancer Chemother Pharmacol 85(2):285–291. https://doi.org/10.1007/s00280-019-03986-0
Kawaguchi K, Miyake K, Han Q, Li S, Tan Y, Igarashi K, Kiyuna T, Miyake M, Higuchi T, Oshiro H, Zhang Z, Razmjooei S, Wangsiricharoen S, Bouvet M, Singh SR, Unno M, Hoffman RM (2018) Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. Cancer Lett 432:251–259. https://doi.org/10.1016/j.canlet.2018.06.016
Park JH, Zhao M, Han Q, Sun Y, Higuchi T, Sugisawa N, Yamamoto J, Singh SR, Clary B, Bouvet M, Hoffman RM (2019) Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model. Biochem Biophys Res Commun 518(2):306–310. https://doi.org/10.1016/j.bbrc.2019.08.051
Sugisawa N, Hamada K, Han Q, Yamamoto J, Sun YU, Nishino H, Kawaguchi K, Bouvet M, Unno M, Hoffman RM (2020) Adjuvant oral recombinant methioninase inhibits lung metastasis in a surgical breast-cancer orthotopic syngeneic model. Anticancer Res 40(9):4869–4874
Hoffman RM (2015) Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer 15(8):451–452. https://doi.org/10.1038/nrc3972
Fu XY, Besterman JM, Monosov A, Hoffman RM (1991) Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci U S A 88(20):9345–9349
Fu X, Guadagni F, Hoffman RM (1992) A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A 89(12):5645–5649
Wang X, Fu X, Hoffman RM (1992) A new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice. Int J Cancer 51(6):992–995
Fu X, Hoffman RM (1993) Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res 13(2):283–286
Fu X, Le P, Hoffman RM (1993) A metastatic orthotopic-transplant nude-mouse model of human patient breast cancer. Anticancer Res 13(4):901–904
Furukawa T, Kubota T, Watanabe M, Kitajima M, Hoffman RM (1993) Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: correlation of metastatic sites in mouse and individual patient donors. Int J Cancer 53(4):608–612
Rashidi B, Gamagami R, Sasson A, Sun FX, Geller J, Moossa AR, Hoffman RM (2000) An orthotopic mouse model of remetastasis of human colon cancer liver metastasis. Clin Cancer Res 6(6):2556–2561
Matsumoto Y, Miwa S, Zhang Y, Hiroshima Y, Yano S, Uehara F, Yamamoto M, Toneri M, Bouvet M, Matsubara H, Hoffman RM, Zhao M (2014) Efficacy of tumor-targeting Salmonella typhimurium A1-R on nude mouse models of metastatic and disseminated human ovarian cancer. J Cell Biochem 115(11):1996–2003. https://doi.org/10.1002/jcb.24871
Tan Y, Xu M, Tan X, Tan X, Wang X, Saikawa Y, Nagahama T, Sun X, Lenz M, Hoffman RM (1997) Overexpression and large-scale production of recombinant L-methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer therapy. Protein Expr Purif 9(2):233–245. https://doi.org/10.1006/prep.1996.0700
Hoffman RM, Jacobsen SJ, Erbe RW (1979) Reversion to methionine independence in simian virus 40-transformed human and malignant rat fibroblasts is associated with altered ploidy and altered properties of transformation. Proc Natl Acad Sci U S A 76(3):1313–1317. https://doi.org/10.1073/pnas.76.3.1313
Stern PH, Mecham JO, Wallace CD, Hoffman RM (1983) Reduced free-methionine in methionine-dependent SV40-transformed human fibroblasts synthesizing apparently normal amounts of methionine. J Cell Physiol 117(1):9–14. https://doi.org/10.1002/jcp.1041170103
Stern PH, Wallace CD, Hoffman RM (1984) Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol 119(1):29–34. https://doi.org/10.1002/jcp.1041190106
Kaiser P (2020) Methionine dependence of cancer. Biomolecules 10(4):568. https://doi.org/10.3390/biom10040568
Gao X, Sanderson SM, Dai Z, Reid MA, Cooper DE, Lu M, Richie JP Jr, Ciccarella A, Calcagnotto A, Mikhael PG, Mentch SJ, Liu J, Ables G, Kirsch DG, Hsu DS, Nichenametla SN, Locasale JW (2019) Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature 572(7769):397–401. https://doi.org/10.1038/s41586-019-1437-3
Stern PH, Hoffman RM (1986) Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst 76(4):629–639. https://doi.org/10.1093/jnci/76.4.629
Hiroshima Y, Zhang Y, Zhang N, Maawy A, Mii S, Yamamoto M, Uehara F, Miwa S, Yano S, Murakami T, Momiyama M, Chishima T, Tanaka K, Ichikawa Y, Bouvet M, Murata T, Endo I, Hoffman RM (2015) Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. PLoS ONE 10(2):e0117417. https://doi.org/10.1371/journal.pone.0117417
Miyake K, Kawaguchi K, Kiyuna T, Miyake M, Igarashi K, Zhang Z, Murakami T, Li Y, Nelson SD, Elliott I, Russell T, Singh A, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Endo I, Eilber FC, Hoffman RM (2018) Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model. Cell Cycle 17(6):722–727. https://doi.org/10.1080/15384101.2017.1423223
Yamamoto J, Murata T, Sugisawa N, Higuchi T, Tashiro Y, Nishino H, Inubushi S, Sun YU, Lim H, Miyake K, Shimoya K, Nomura T, Kurebayashi J, Tanino H, Hozumi C, Bouvet M, Singh SR, Endo I, Hoffman RM (2020) Eribulin regresses a cisplatinum-resistant rare-type triple-negative matrix-producing breast carcinoma patient-derived orthotopic xenograft mouse model. Anticancer Res 40(5):2475–2479
Acknowledgements
This paper is dedicated to the memory of A. R. Moossa, M.D., Sun Lee, M.D., Professor Li Jiaxi, and Masaki Kitajima, M.D.
Funding
The study was funded in part by the Robert M. Hoffman Foundation for Cancer Research.
Author information
Authors and Affiliations
Contributions
NS and RMH: Project development. NS, CH, and TM: Data collection. NS, TH, QH, CH, JY, YT, HN, KK, MB, TM, MU, and RMH: Analysis and interpretation of data. NS and RMH: Writing, review, and revision of the manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that there are no potential conflicts of interest. AntiCancer, Inc. uses PDOX mouse models for contract research. QH is an employee of AntiCancer, Inc. NS, TH, JY, YT, HN, and RMH are or were unsalaried associates of AntiCancer, Inc.
Ethical approval
The mouse experiments were carried out under an AntiCancer, Inc. Institutional Animal Care and Use Committee (IACUC) approved protocol using guidelines of the National Institutes of Health Guide for the Care and Use of Animals, under Assurance Number A3873-1.
Consent to participate
Written informed consent was provided by the patient as a part of an approved protocol by the Institutional Review Board (IRB) of Kawasaki Medical School.
Consent for publication
All authors agree with the contents of the present manuscript and for submission to Cancer Chemotherapy and Pharmacology.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sugisawa, N., Higuchi, T., Han, Q. et al. Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Cancer Chemother Pharmacol 88, 61–67 (2021). https://doi.org/10.1007/s00280-021-04261-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-021-04261-x